Rapid expansion PetCure Oncology operates a growing national network across eight U.S. cities with multiple affiliated centers, including partnerships with Thrive Pet Healthcare. This expansion indicates demand for their SRS/SRT services and presents a sales opportunity to broaden referral channels, hospital partnerships, and shared marketing initiatives in new markets.

Advanced radiotherapy The company specializes in stereotactic radiation therapy (SRS/SRT) for pets, a high-precision, non-surgical treatment that aligns with cutting-edge human medicine standards. This positions PetCure as a premium partner for veterinary practices seeking to offer advanced cancer care, suggesting opportunities to license technology, co-brand services, or integrate referral programs with clinics lacking SRS/SRT capability.

Scientific leadership A Scientific Advisory Board comprising human and veterinary oncologists and medical physicists supports outcome-driven care protocols. This focus on data-driven excellence can be leveraged to build trust with potential clients and summarily pitch collaborative research, clinical trials, and data-sharing partnerships to veterinary networks seeking evidence-backed treatments.

Clinical milestones Historical milestones include the launch of fiducial-guided SRT partnerships and collaboration with Varian’s Halcyon system, plus early clinical trials for canine lung tumors. These milestones signal a track record of innovation and capability, providing talking points for sales outreach to veterinary institutions and hospitals looking to upgrade their oncology offerings.

Brand and reach With a revenue range of $1M-$10M and a focused business model supported by digital tools and partner networks, PetCure Oncology demonstrates a scalable boutique oncology platform. This suggests opportunities to position as a managed services partner, offer co-marketing, referral incentives, and enrollment support for clinics aiming to enhance their oncology portfolios.